NEW YORK (GenomeWeb News) – Diagnostic firm Theradiag today announced a partnership with French organizations to develop diagnostic and theranostic tools for rheumatoid arthritis.
The agreement between Theradiag, the French National Center for Scientific Research/The Institute of Molecular Genetics of Montpellier, and the Universities of Montpellier 1 and 2 is focused on identifying microRNA signatures to improve the ability of tests to diagnose RA, to analyze disease activity and severity of the disease, and to predict response to therapies.
The development program will have an initial cohort of 100 patients, Theradiag said.
Financial and other terms of the deal were not disclosed.